1. Cardiorespiratory fitness, physical activity and cancer mortality in men;Vainshelboim;Prev. Med.,2017
2. Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects;Antonello;J. Med. Chem.,2006
3. a) T. Ishikawa, M. Seto, H. Banno, Y. Kawakita, M. Oorui, T. Taniguchi, Y. Ohta, T. Tamura, A. Nakayama, H. Miki, H. Kamiguchi, T. Tanaka, N. Habuka, S. Sogabe, J. Yano, K. Aertgeerts, K. Kamiyama, Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold, J. Med. Chem. 54(23) (2011) 8030–50. b) Y. Ji, Q. Sun, J. Zhang, H. Hu, MiR-615 inhibits cell proliferation, migration and invasion by targeting EGFR in human glioblastoma, Biochem. Biophys. Res. Commun. 499(3) (2018) 719–726. c) X. Qu, L. Yang, Q. Shi, X. Wang, D. Wang, G. Wu, Lidocaine inhibits proliferation and induces apoptosis in colorectal cancer cells by upregulating mir-520a-3p and targeting EGFR, Pathol. Res. Pract. 214(12) (2018) 1974–1979. d) C. Yewale, D. Baradia, I. Vhora, S. Patil, A. Misra, Epidermal growth factor receptor targeting in cancer: a review of trends and strategies, Biomaterials 34(34) (2013) 8690–707.
4. a) D.S. Salomon, R. Brandt, F. Ciardiello, N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies, Crit. Rev. Oncol. Hematol. 19(3) (1995) 183–232. b) D. Das, L. Xie, J. Wang, X. Xu, Z. Zhang, J. Shi, X. Le, J. Hong, Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities–Part 1, Bioorg. Med. Chem. Lett. 29(4) (2019) 591–596. c) N. Tebbutt, M.W. Pedersen, T.G. Johns, Targeting the ERBB family in cancer: couples therapy, Nature reviews. Cancer 13(9) (2013) 663–73. d) J. Zhang, P.L. Yang, N.S. Gray, Targeting cancer with small molecule kinase inhibitors, Nature reviews. Cancer 9(1) (2009) 28–39.
5. a) L.V. Sequist, R.G. Martins, D. Spigel, S.M. Grunberg, A. Spira, P.A. Jänne, V.A. Joshi, D. McCollum, T.L. Evans, A. Muzikansky, G.L. Kuhlmann, M. Han, J.S. Goldberg, J. Settleman, A.J. Iafrate, J.A. Engelman, D.A. Haber, B.E. Johnson, T.J. Lynch, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations, J. Clin. Oncol. 26(15) (2008) 2442–2449. b) J.C. Yang, J.Y. Shih, W.C. Su, T.C. Hsia, C.M. Tsai, S.H. Ou, C.J. Yu, G.C. Chang, C.L. Ho, L.V. Sequist, A.Z. Dudek, M. Shahidi, X.J. Cong, R.M. Lorence, P.C. Yang, V.A. Miller, Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial, Lancet Oncol. 13(5) (2012) 539–548. c) H.A. Burris, 3rd, Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib, Oncologist 9 Suppl 3 (2004) 10–5. d) Z. Yang, A. Hackshaw, Q. Feng, X. Fu, Y. Zhang, C. Mao, J. Tang, Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis, Int. J. Cancer 140(12) (2017) 2805–2819.